Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 124,16 € (+14,33 %). La mediana es de 127,38 € (+17,29 %).
| Comprar |
24 |
| Mantener |
20 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Incyte presents ambitious pipeline plan and expects strong revenue growth
At the Wells Fargo Healthcare Conference, Incyte outlined a strategy to move the company away from dependence on Jakafi toward multiple franchises. Management expects double‑digit growth for the core business excluding Jakafi by 2030, with revenues of $3–4 billion and a peak pipeline revenue potential of $8–10 billion, driven by programs such as G12D, TGF‑beta‑PD‑1, INCA33989, VGA039 and povorcitinib. Key upcoming milestones include phase‑III data for G12D and TGF‑beta, FDA clarifications for INCA33989, and the targeted approval of povorcitinib in 2027. » Más en de.investing.com
Incyte receives EU approval for Opzelura to treat moderate atopic dermatitis
The European Commission has approved Opzelura (ruxolitinib) from Incyte for topical treatment of moderate atopic dermatitis in adults when corticosteroids and calcineurin inhibitors are unsuitable or ineffective. The approval is based on phase‑3 data, notably the TRuE‑AD4 study with 241 patients, in which Opzelura showed significant improvements in EASI‑75 and IGA‑TS after eight weeks and achieved high success rates after 24 weeks of 84.3% (EASI‑75) and 70.6% (IGA‑TS). Common adverse events were upper respiratory tract infections and nasopharyngitis; serious infections, cardiovascular events, malignancies, or thromboses were not reported during the 24‑week observation period. » Más en de.investing.com
Incyte reaches 52-week high of 119.60 USD
Incyte shares rose to a new 52-week high of 119.60 USD and gained 68.7% over the past year. Market capitalization is 23.74 billion USD, the P/E ratio is 16.68 and revenue growth over the last twelve months is 21.48%. Incyte also signed a global licensing agreement with Halozyme for subcutaneous development of INCA033989, is preparing data presentations for the ESMO Congress 2026, and received positive analyst reactions including a buy rating from H.C. Wainwright (price target 140 USD). BMO raised its price target to 112 USD after strong Opzelura revenue forecasts for Q2 2026. » Más en de.investing.com
Incyte to present data on six oncology programs at ESMO 2026
Incyte will present data from six oncology programs at the ESMO 2026 congress, including phase‑1 results for INCB161734 (oral KRAS‑G12D inhibitor) and INCA33890 (bispecific TGFβR2×PD‑1 antibody). The company will feature four rapid oral presentations and two posters, including final survival data from the phase‑3 POD1UM‑303/InterAACT‑2 study on retifanlimab and data on INCB123667 in combination with bevacizumab. The first two agents are also being investigated in parallel phase‑3 programs as first‑line therapies for pancreatic cancer and microsatellite‑stable colorectal cancer, respectively. The announcement highlights a robust pipeline; the stock is trading near its 52‑week high, and the company is reported to have solid revenue growth and a strong balance sheet. » Más en de.investing.com
Incyte hits 52-week high at $118.98
Incyte shares climbed to a new 52-week high of $118.98; market capitalization stands at $23.71 billion and the P/E ratio at 16.44. Over the past year the stock rose 74.24% and InvestingPro rates the company as undervalued with excellent financial health. Incyte completed the $1.25 billion acquisition of Vega Therapeutics, adding VGA039 (phase-3) to its hematology portfolio; the company also reported positive phase-1/2 data for latarcibart. Analysts reacted positively: H.C. Wainwright reiterated "Buy", Citizens left its rating at "Market Perform" and BMO Capital raised its price target to $112. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 1374,78 M | 18,11 % |
| Beneficio bruto | 1278,77 M | 18,45 % |
| Beneficio neto | -692,86 M | 291,69 % |
| EBITDA | -607,62 M | 240,66 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 22,09 mil M € |
Número de acciones | 203,83 M |
Máximo/mínimo de 52 semanas | 120,64 € - 81,20 € |
| Dividendos | No |
Beta | 0,78 |
Ratio P/E | 56,71 |
Ratio PEG | -0,86 |
Ratio P/B | 4,29 |
Ratio P/S | 4,04 |
Perfil de la empresa
Incyte Corporation, una empresa biofarmacéutica, se centra en el descubrimiento, desarrollo y comercialización de terapias patentadas en Estados Unidos y a nivel internacional. La compañía ofrece JAKAFI, un fármaco para el tratamiento de la mielofibrosis y la policitemia vera; PEMAZYRE, un inhibidor de la quinasa del receptor del factor de crecimiento de fibroblastos que actúa como impulsor oncogénico en diversos tipos de tumores líquidos y sólidos; e ICLUSIG, un inhibidor de quinasas para tratar la leucemia mieloide crónica y la leucemia linfoblástica aguda positiva para el cromosoma Filadelfia. Sus productos en fase clínica incluyen ruxolitinib, para la enfermedad crónica de injerto contra huésped (EICH) refractaria a esteroides; itacitinib, que se encuentra en un ensayo clínico de fase II/III para tratar la EICH crónica en pacientes naïve; y pemigatinib para el tratamiento del cáncer de vejiga, colangiocarcinoma, síndrome mieloproliferativo y tumores agnósticos. Además, la compañía desarrolla parsaclisib, que se encuentra en un ensayo clínico de fase II para el linfoma folicular, el linfoma de zona marginal y el linfoma de células del manto. Asimismo, desarrolla retifanlimab, que se encuentra en ensayos clínicos de fase II para el cáncer de endometrio con inestabilidad de microsatélites alta, el carcinoma de células de Merkel y el cáncer anal, así como en ensayos clínicos de fase II para pacientes con cáncer de pulmón de células no pequeñas. Tiene acuerdos de colaboración con Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; y Nimble Therapeutics, además de colaboraciones clínicas con MorphoSys AG y Xencor, Inc. para investigar la combinación de tafasitamab, plamotamab y lenalidomida en pacientes con linfoma difuso de células B grandes recidivante o refractario, y con linfoma folicular recidivante o refractario. La compañía se constituyó en 1991 y tiene su sede en Wilmington, Delaware.
| Nombre | Incyte Co. |
| CEO | William J. Meury |
| Sede | Wilmington,
de Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 04/11/1993 |
| Empleados | 2844 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | INCY |
London Stock Exchange | 0J9P.L |
Frankfurt | ICY.F |
Düsseldorf | ICY.DU |
Milan | 1INCY.MI |
London | 0J9P.L |
SIX | ICY.SW |
München | ICY.MU |